Candel Therapeutics Inc (NASDAQ:CADL) does about 2.42M shares in volume on a normal day but saw 18606225 shares change hands in the recent trading day. The company now has a market cap of 150.99M USD. Its current market price is $6.75, marking a decrease of -31.12% compared to the previous close of $9.80. The 52 week high reached by this stock is $14.60 whilst the lowest price level in 52 weeks is $1.02.
Candel Therapeutics Inc (CADL) has a 20-day trading average at $5.08 and the current price is -53.77% off the 52-week high compared with 561.76% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.35 and its 200-day simple moving average is $5.95. If we look at the stock’s price movements over the week, volatility stands at 42.85%, which decreases to 19.32% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 56.74 to suggest the stock is neutral.
The consensus objective for the share price is $11.00, suggesting that the stock has a potential upside of 38.64% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 02, 2022 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $11. UBS initiated its price target at $9.
The current price level is 32.97%, 26.17%, and 13.50% away from its SMA20, SMA50, and SMA200 respectively, with the CADL price moving below the 50-day SMA on current market day. Candel Therapeutics Inc (CADL) stock is up 31.32% over the week and 57.34% over the past month. Its price is 359.18% year-to-date and 467.23% over the past year.
To reach the target analysts have set, the stock logically needs to grow 38.64 percent from here.
The company has a return on equity of -1344.47%. The forward price to earnings ratio is 45.00. The beta has a value of -1.00.
